Strategy
Our strategy is based on four core components:
PORTFOLIO MODEL
We are developing a large and diversified portfolio of novel therapeutics with uncorrelated risk. We currently have five programs in development and over 15 more programs in discovery and preclinical development.
We focus on programs that have the potential to be first-in-class and/or best-in-class in major commercial markets. We are agnostic to indication and program selection is primarily driven by the strength of the scientific hypothesis and supporting evidence, together with the potential to transform the standard of care in major commercial markets.
We have core competencies in biology and small molecule and monoclonal antibody discovery. Where applicable we use human genetics, particularly Mendelian randomization, to infer disease causality for molecular targets that form the basis of our programs.